Dazucorilant

Small molecule

Phase 2topline reported

Evidence outlook

Amyotrophic Lateral Sclerosis: topline reported 2024-12

The sponsor reported topline results in 2024-12 (Phase 2 DAZALS (NCT05407324) of dazucorilant in ALS did not meet its primary endpoint (change in ALSFRS-R)). The announcement is listed under Regulatory events.

Latest reported trial: NCT05407324 · Phase 2 · missed primary endpoint · grade pending

Featured evidence outside this drug's tracked markets:NCT06495944 · Healthy Adults · Phase 1 · completed · ungraded

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Amyotrophic Lateral Sclerosis
Phase 1 (5)
Other / comorbidity
NCT06928779 · Corcept Therapeutics
2024-10-08 – 2024-12-09 · Hepatic Impairment
What this study did
NCT06495944 · Corcept Therapeutics
2024-05-31 – 2024-08-02 · Healthy Adults
What this study did
NCT04994743 · Corcept Therapeutics
2021-07-13 – 2021-09-30 · Healthy Adults
What this study did
NCT04990310 · Corcept Therapeutics
2021-08-18 – 2021-09-20 · Healthy
What this study did
NCT04249323 · Corcept Therapeutics
2020-01-27 – 2020-10-15 · Healthy Adults
What this study did

Competitive landscape

This mechanism is crowded: 23 other tracked programmes target it, 22 of them ahead of this one.

This drug's own stage for Amyotrophic Lateral Sclerosis: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Dazucorilant: this drugPhase 2Small moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Albuterol / Budesonide (Airsupra)
Approved(overall)
CombinationBeta-2 adrenergic receptor, Glucocorticoid receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Beclomethasone (QVAR)
Approved(overall)
Small moleculeGlucocorticoid receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Betamethasone Dipropionate Emollient Spray (Sernivo)
Approved(overall)
Small moleculeGlucocorticoid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Budesonide (Entocort EC)
Approved(overall)
Small moleculeGlucocorticoid receptor
Weak signal(overall)
No reviewed efficacy summary in this indication
Budesonide (Ortikos)
ApprovedUS marketing discontinued (overall)
—Glucocorticoid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Budesonide (targeted-Release) (TARPEYO / Nefecon)
Approved(overall)
Small moleculeGlucocorticoid receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Budesonide (Uceris Rectal Foam)
Approved(overall)
Small moleculeGlucocorticoid receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Budesonide MMX (Uceris)
Approved(overall)
Small moleculeGlucocorticoid receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Ciclesonide (Alvesco)
Approved(overall)
Small moleculeGlucocorticoid receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Dexamethasone
Approved(overall)
Small moleculeGlucocorticoid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Dexamethasone (Dextenza)
Approved(overall)
Small moleculeGlucocorticoid receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Edaravone (Radicava ORS)ApprovedSmall moleculeReactive oxygen species (ROS)Weak signalFeatured results are safety only in this race
Fluticasone Furoate (Arnuity Ellipta)
Approved(overall)
Small moleculeGlucocorticoid receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Fluticasone Furoate / Umeclidinium / Vilanterol (Trelegy Ellipta)
Approved(overall)
Small moleculeMuscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination)
Reliable signal(overall)
No reviewed efficacy summary in this indication
Fluticasone Furoate / Vilanterol (Breo Ellipta)
Approved(overall)
Small moleculeBeta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Fluticasone Propionate
Approved(overall)
Small moleculeGlucocorticoid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Fluticasone Propionate / Salmeterol (Advair HFA)
Approved(overall)
CombinationGlucocorticoid receptor / Beta-2 adrenergic receptor, Beta-2 adrenergic receptor, Glucocorticoid receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Halobetasol Propionate Foam (Lexette)
ApprovedUS marketing discontinued (overall)
Small moleculeGlucocorticoid receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Halobetasol Propionate Lotion (Bryhali)
Approved(overall)
Small moleculeGlucocorticoid receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Hydrocortisone (Cortenema)
Approved(overall)
Small moleculeGlucocorticoid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Hydrocortisone Acetate (Cortifoam)
Approved(overall)
Small moleculeGlucocorticoid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Relacorilant (Lifyorli)
Approved(overall)
Small moleculeGlucocorticoid receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Tofersen (Qalsody)ApprovedRNA / oligonucleotideSOD1Partial signalNo reviewed efficacy summary in this indication
Lodotra (Rayos)
US approval withdrawn(overall)
—Glucocorticoid receptor
Weak signal(overall)
No reviewed efficacy summary in this indication
MasitinibPhase 3Small moleculeKIT (c-Kit), also PDGFR and Lyn/Fyn kinasesnot yet gradedNo reviewed efficacy summary in this indication
UlefnersenPhase 3RNA / oligonucleotideFUSReliable signal
NCT04768972: FUSION (NCT04768972): ulefnersen met its primary endpoint, a joint rank (win-ratio style) analysis of time to death/permanent ventilation, time to rescue, and change in ALSFRS-R score to Day 505 vs placebo; p=0.0005.
CB03-154Phase 2/3Small moleculeKCNQ2/3 (Kv7.2/7.3) potassium channel (opener)not yet gradedNo reviewed efficacy summary in this indication
CNM-Au8Phase 2/3Nanoparticlemitochondrial energy metabolismnot yet gradedNo reviewed efficacy summary in this indication
IbudilastPhase 2/3Small moleculePDE4 and PDE10; macrophage migration inhibitory factor (MIF)not yet gradedNo reviewed efficacy summary in this indication
Tazbentetol (SPG302)Phase 2/3Small moleculeDendritic spine densityWeak signalFeatured results are safety only in this race
ForalumabPhase 2Monoclonal antibodyCD3not yet gradedNo reviewed efficacy summary in this indication
Miricorilant
Phase 2(overall)
Small moleculeGlucocorticoid receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
ALN-SODPhase 1/2RNA / oligonucleotideSOD1not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

December 2024Topline resultPhase 2 DAZALS (NCT05407324) of dazucorilant in ALS did not meet its primary endpoint (change in ALSFRS-R)
Corcept Therapeutics · Source ↗